Federated Hermes Inc. Has $10.08 Million Position in Rezolute, Inc. (NASDAQ:RZLT)

Federated Hermes Inc. raised its position in Rezolute, Inc. (NASDAQ:RZLT) by 53.6% in the 4th quarter, Holdings Channel.com reports. The firm owned 10,154,327 shares of the company’s stock after buying an additional 3,544,053 shares during the period. Federated Hermes Inc. owned approximately 0.26% of Rezolute worth $10,083,000 at the end of the most recent quarter.

Rezolute Stock Performance

Shares of NASDAQ RZLT opened at $2.86 on Wednesday. The company’s 50 day moving average price is $2.13 and its 200-day moving average price is $1.36. Rezolute, Inc. has a 52-week low of $0.72 and a 52-week high of $3.69. The company has a market capitalization of $114.77 million, a P/E ratio of -2.60 and a beta of 1.29.

Rezolute (NASDAQ:RZLT) last released its earnings results on Tuesday, February 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.27). Analysts forecast that Rezolute, Inc. will post -1.06 earnings per share for the current year.

Insider Activity

In other Rezolute news, CFO Daron Evans bought 50,000 shares of the stock in a transaction on Friday, March 8th. The stock was acquired at an average cost of $1.93 per share, for a total transaction of $96,500.00. Following the completion of the acquisition, the chief financial officer now owns 120,900 shares in the company, valued at approximately $233,337. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, Director Young-Jin Kim acquired 36,503 shares of the firm’s stock in a transaction dated Thursday, March 7th. The stock was purchased at an average price of $1.91 per share, for a total transaction of $69,720.73. Following the completion of the acquisition, the director now directly owns 115,450 shares in the company, valued at approximately $220,509.50. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Daron Evans bought 50,000 shares of the business’s stock in a transaction that occurred on Friday, March 8th. The stock was purchased at an average price of $1.93 per share, for a total transaction of $96,500.00. Following the completion of the acquisition, the chief financial officer now owns 120,900 shares in the company, valued at $233,337. The disclosure for this purchase can be found here. Insiders have acquired 179,403 shares of company stock valued at $306,601 in the last ninety days. 18.20% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. JMP Securities reaffirmed a “market outperform” rating and issued a $7.00 price objective on shares of Rezolute in a research note on Thursday, April 18th. HC Wainwright reaffirmed a “buy” rating and set a $14.00 price target on shares of Rezolute in a research note on Thursday, March 7th. Maxim Group started coverage on shares of Rezolute in a research note on Tuesday, April 9th. They issued a “buy” rating and a $8.00 price objective on the stock. Finally, Jonestrading initiated coverage on Rezolute in a research report on Thursday, April 18th. They set a “buy” rating and a $10.00 target price for the company. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Rezolute presently has a consensus rating of “Buy” and an average target price of $8.80.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.